AbbVie paid Alector $225 million up front five years ago to begin an R&D partnership on two drugs intended to bring an immunotherapy approach to the treatment of Alzheimer’s disease. One of the drugs has reached Phase 2 testing but the pharmaceutical giant has terminated the alliance on a program in Phase 1.
GlaxoSmithKline is paying Alector $700 million up front to share in the development of the biotech’s two lead drugs, which offer potentially broad application in treating neurological disorders. Alector’s approach addresses the role immune cell dysfunction plays in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The VC firm, started by the former heads of Foundation Medicine and Google Ventures, is raising $350 million for its third fund, according to a filing with the Securities and Exchange Commission.
The "immuno-neurology" company expects to raise $176 million in the offering, which it expects to close on Monday.
The company has a "unique" approach to treating Alzheimer's, CEO Arnon Rosenthal says - taking an immunotherapy approach to neurodegenerative disease.
Immunotherapy startup Alector just raised $32 million to expand its pipeline of immune system-modulating drugs for neurodegenerative disease. The "hypothesis-driven" company has a bold approach to this family of disease, which has few effective therapies.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.